Robert Weinstein was named Chief Accounting Officer of Petros Pharmaceuticals, Inc. As of November 6, 2026, Petros Pharmaceuticals, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 18, 2026 to September 30, 2026, naming 1 appointment (Form 8-K, June 18, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Petros Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Petros Pharmaceuticals, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-18 to 2026-09-30. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Petros Pharmaceuticals, Inc. files it.
Also on the record for Petros Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 17, 2026 | Stake report, Schedule 13G/A, by Iroquois Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| August 15, 2025 | Stake report, Schedule 13G/A, by Iroquois Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Petros Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Petros Pharmaceuticals, Inc. and the records around it.
Petros Pharmaceuticals, Inc. elsewhere on the record
Companies that share a holder
- Iroquois Capital Management, LLC also filed stake reports on 13 other companies: 22nd Century Group (Aug 2026), XWELL, Inc. (Aug 2026), Clearmind Medicine Inc. (Aug 2026)
Watch Petros Pharmaceuticals, Inc.
Get an email when Petros Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Petros Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Petros Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Petros Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-30 | Reported | not named in the filing | 8-K, 2026-09-30 | ||
| 2026-06-18 | In | Chief Accounting Officer | 8-K, 2026-06-18 |
Who leads Petros Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Accounting Officer: Robert Weinstein, appointed (filed 2026-06-18).
New leaders reset buying decisions — get the Full Report on Petros Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Accounting Officer at Petros Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Chief Accounting Officer at Petros Pharmaceuticals, Inc.Every change, in the filing's words
Reported
In connection with the ABC, the following members of the Company's Board of Directors have resigned effective as of September 30, 2026: Joshua N. Silverman, Executive Chairman Bruce T. Bernstein, Director Wayne R. Walker, Director On September 30, 2026, Fady Boctor was terminated as President and Chief Commercial Officer of the Company.
- In addition, effective as of September 30, 2026 at 5:30 p.m.
- Eastern time, Robert Weinstein resigned as Chief Accounting Officer, Principal Financial Officer, and Principal Accounting Officer of the Company.
- These resignations or termination, as applicable, were not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- Actual results may differ materially from those expressed or implied due to various factors, including the Assignee's ability to administer the assets and claims effectively.
Appointed: Robert Weinstein, Chief Accounting Officer
On June 18, 2026, the board of directors (the "Board") of the Company appointed Robert Weinstein to the positions of Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective immediately.
- Mutual Separation with Mitchell Arnold On June 18, 2026, Petros Pharmaceuticals, Inc. (the "Company") and Mitchell Arnold, who served as the Company's Vice President of Finance, Principal Accounting Officer and Principal Financial Officer, mutually agreed to the separation of Mr. Arnold from such roles, effective as of June 18, 2026 (the "Separation Date").
- The terms of Mr. Arnold's separation from the Company have been memorialized pursuant to a General Release and Severance Agreement, dated as of June 18, 2026 (the "Separation Agreement").
- In exchange for the consideration provided to Mr. Arnold in the Separation Agreement, Mr. Arnold agreed to waive and release any claims in connection with Mr. Arnold's employment and separation from the Company.
- The Separation Agreement provides Mr. Arnold with 21 days to review the Separation Agreement prior to accepting it.
- The Separation Agreement further provides that Mr. Arnold may revoke his acceptance of the Separation Agreement within seven calendar days of his execution thereof.
- The Separation Agreement shall become enforceable on the eighth day following Mr. Arnold's execution thereof if he does not revoke his acceptance of the Separation Agreement by written notice before such time.
Tools for this story
Each opens in a new tab, filled in for Petros Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.